Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most patients (57%) were diagnosed as having SARS-CoV-2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty-six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS-CoV-2 infection was six years (three months to 18 years). Twenty-one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty-three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID-19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS-CoV-2 infection and an impact of the pandemic on the overall management of CML patients.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report / Breccia M.; Abruzzese E.; Accurso V.; Attolico I.; Barulli S.; Bergamaschi M.; Binotto G.; Bocchia M.; Bonifacio M.; Caocci G.; Capodanno I.; Castagnetti F.; Cavazzini F.; Crisa E.; Crugnola M.; Stella De Candia M.; Elena C.; Fava C.; Galimberti S.; Gozzini A.; Gugliotta G.; Intermesoli T.; Iurlo A.; La Barba G.; Latagliata R.; Leonetti Crescenzi S.; Levato L.; Loglisci G.; Lucchesi A.; Luciano L.; Lunghi F.; Luzi D.; Malato A.; Cristina Miggiano M.; Pizzuti M.; Pregno P.; Rapezzi D.; Rege-Cambrin G.; Rosti G.; Russo S.; Sancetta R.; Rita Scortechini A.; Sora F.; Sportoletti P.; Stagno F.; Tafuri A.; Tiribelli M.; Foa R.; Saglio G.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - STAMPA. - 196:3(2022), pp. 559-565. [10.1111/bjh.17890]
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report
Castagnetti F.;Gugliotta G.;Lucchesi A.;
2022
Abstract
Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most patients (57%) were diagnosed as having SARS-CoV-2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty-six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS-CoV-2 infection was six years (three months to 18 years). Twenty-one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty-three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID-19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS-CoV-2 infection and an impact of the pandemic on the overall management of CML patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
